

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

Final Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company Novartis Pharmaceuticals (ruxolitinib) Patient/carer groups African-Caribbean Leukaemia Trust Anthony Nolan Aplastic Anaemia Trust Blood Cancer UK Chronic Myeloid Leukaemia Support Group Cianna's Smile DKMS Immunodeficiency UK Leukaemia Cancer Society Leukaemia Care Lymphoma Action Macmillan Cancer Support MDS UK Patient Support Group MPS Society Myeloma UK	 General All Wales Adult Inherited Metabolic Disease Service Cardiff All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Hospital Information Services – Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Services Division
 MDS UK Patient Support Group MPS Society Myeloma UK Sickle Cell and Young Stroke Survivors Sickle Cell Society 	 National Association of Primary Care National Pharmacy Association National Services Division NHS Confederation Scottish Medicines Consortium Welsh Government
 SickleKan South Asian Health Foundation Specialised Healthcare Alliance The Essenelle Foundation UK Thalassaemia Society 	 Welsh Health Specialised Services Committee Comparator companies Pfizer (sirolimus) Roche Products (mycophenolate
 Healthcare professional groups British Blood Transfusion Society British Committee for Standards in Haematology British Geriatrics Society British Paediatric Allergy, Immunity and Infection Group (BPAIIG) 	 mofetil) Rosemont Pharmaceuticals (mycophenolate mofetil) Teva Pharma (mycophenolate mofetil) Tillomed Laboratories (mycophenolate mofetil)


Final stakeholder list for the evaluation of Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Issue date: April 2024



Consultees Commentators (no right to submit or appeal) British Society for Genetic Medicine Relevant research groups British Society for Haematology Cochrane Haematological Malignancies British Society for Immunology Group British Society of Blood and Marrow Cochrane UK Transplantation and Cellular Therapy Genomics England **British Transplantation Society** Leukaemia Busters Cancer Research UK MRC Clinical Trials Unit Neonatal and Paediatric Pharmacists National Institute for Health Research Group Oxford Biomedical Research Centre NHS Blood and Transplant Royal College of General Practitioners Associated Public Health groups Royal College of Nursing Public Health Wales Royal College of Paediatrics and Child **UK Health Security Agency** Health Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine **UK Clinical Pharmacy Association** UK Forum on Haemoglobin Disorders **UK Primary Immunodeficiency** Network Others Christie Haematology and Transplant Unit (Manchester) Department of Health and Social Care King's College London - Haematooncology department **NHS** England St James University Hospital Bone Marrow Transplant Department (Leeds Teaching Hospitals Trust) University College London Hospitals **HSCT Service**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Final stakeholder list for the evaluation of Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] Issue date: April 2024



Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.